Mode
Text Size
Log in / Sign up

GBA1 L444P carriers have ninefold higher odds of Parkinson's disease than non-carriers

GBA1 L444P carriers have ninefold higher odds of Parkinson's disease than non-carriers
Photo by Trust "Tru" Katsande / Unsplash
Key Takeaway
Consider that GBA1 L444P carrier status strongly associates with higher Parkinson's disease odds for genetic counseling.

This is a systematic review and meta-analysis synthesizing genetic association data for Parkinson's disease. The scope was to estimate the odds of Parkinson's disease in heterozygous GBA1 L444P carriers versus non-carriers, using data from 33,752 patients and 34,101 controls across multiple continents.

The authors found that heterozygous GBA1 L444P carriers had markedly higher odds of Parkinson's disease than non-carriers. The pooled effect size was an odds ratio of 9.19 (95% CI 6.94 to 12.16), indicating a strong association.

Key limitations noted by the authors include wide confidence intervals in several ancestry subgroups, which highlight imprecision due to sparse data and internal heterogeneity. The review does not report safety data, as this is a genetic association study.

The authors suggest that these findings can inform genetic counseling and Parkinson's disease risk discussions. The practice relevance is to support risk stratification based on GBA1 L444P carrier status, though the association does not imply causality.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedJun 2026
View Original Abstract ↓
INTRODUCTION AND OBJECTIVE: Mutations in the GBA1 gene, particularly the severe L444P variant, are among the strongest known genetic risk factors for Parkinson's disease (PD). Prior meta-analyses published before 2018 included fewer studies and often pooled multiple mutations, prompting this updated, mutation-specific systematic review and meta-analysis. METHODS: Standard systematic review and meta-analytic methods were used, including predefined eligibility criteria, literature search, and pooled analysis of odds ratios (ORs) for PD in GBA1 L444P carriers versus non-carriers. RESULTS: We included 51 studies comprising 33,752 PD patients and 34,101 controls across multiple continents. In random-effects meta-analysis, heterozygous GBA1 L444P carriers had markedly higher odds of PD than non-carriers (pooled OR 9.19, 95% CI 6.94-12.16), with similar estimates across sensitivity and leave-one-out analyses. Cumulative meta-analysis showed early variability but stable pooled ORs around 7-9 from 2008 to 2010 onward. Ancestry-specific pooled ORs were consistently elevated across populations, with overlapping confidence intervals and no significant subgroup differences. Funnel and Galbraith plots and Egger's test showed no evidence of substantial small-study effects or publication bias. CONCLUSIONS: This updated synthesis demonstrates that heterozygous GBA1 L444P carriage confers a consistently large increase in PD risk across populations, with robust pooled estimates across multiple sensitivity analyses. Although overall statistical heterogeneity was negligible, wide confidence intervals in several ancestry subgroups highlight imprecision due to sparse data and internal heterogeneity, underscoring the need for broader and more equitable genetic testing, improved risk estimation in underrepresented populations, and targeted research on severe GBA1 variants to inform genetic counseling and PD risk discussions. REGISTRATION: PROSPERO Registration Number: CRD420251182022. Registration details available at the PROSPERO database.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.